Publications by authors named "Allison Florance"

Claim this Profile
Q
Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Richard S Finn, Michael F Press, Judy Dering, Lisa O'Rourke, Allison Florance

Clin Cancer Res· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.
Frankie Ann Holmes, Virginia Espina, Lance A Liotta, Yasir M Nagarwala, Michael Danso, Allison Florance

BMC Res Notes· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.
Francisco J Esteva, Sandra X Franco, Maura K Hagan, Abenaa M Brewster, Robert A Somer, Allison M Florance

Oncologist· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Kimberly L Blackwell, Harold J Burstein, Anna Maria Storniolo, Hope S Rugo, George Sledge, Allison Florance

J Clin Oncol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
Lee S Schwartzberg, Sandra X Franco, Allison Florance, Lisa O'Rourke, Julie Maltzman

Oncologist· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Stephen Johnston, John Pippen, Xavier Pivot, Mikhail Lichinitser, Saeed Sadeghi, Allison Florance

J Clin Oncol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study).
Princy N Kumar, Patricia Salvato, Anthony LaMarca, Edwin DeJesus, Parul Patel, Allison Florance

AIDS Res Ther· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).
Nestor Sosa, Christina Hill-Zabala, Edwin Dejesus, Gisella Herrera, Allison Florance

J Acquir Immune Defic Syndr· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms.
Lisa Ross, Ronan Boulmé, Robin Fisher, Jaime Hernandez, Allison Florance

AIDS Res Hum Retroviruses· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of HIV type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms: an analysis of a subpopulation of the CHORUS cohort.
Lisa Ross, Ronan Boulmé, Gregory Fusco, Anthony Scarsella, Allison Florance

AIDS Res Hum Retroviruses· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis